Genpact Accelerates Strategy to Establish New Industry Standard for Pharmacovigilance Using AI and Machine Learning Technologies

0
309

ACQUISITION OF COMMONWEALTH INFORMATICS FURTHER STRENGTHENS GENPACT’S
PHARMACOVIGILANCE AI CAPABILITIES TO HELP TRANSFORM DRUG SAFETY_

New York, June 20, 2018: Genpact (NYSE: G), a professional services
firm focused on delivering digital transformation, announced that it has
signed a definitive agreement to acquire Commonwealth Informatics, Inc.
(CI), a market-leading provider of cloud-based drug safety analytics
products and services for medical research and healthcare delivery
headquartered near Boston, Mass. Terms of the deal were not disclosed.
This transaction is not expected to be material to current year
financial performance.

With this acquisition, the Genpact pharmacovigilance artificial
intelligence (PVAI) suite of capabilities is expected to be the first in
the industry to establish a closed-loop, machine-learning system across
the entire pharmacovigilance information value chain. Incorporating the
Commonwealth Vigilance Workbench (CVW) software and the deep expertise
of the CI team, Genpact will enable life sciences companies to establish
a new approach for pharmacovigilance – one which leverages the wealth of
available data in an effort to better predict and prevent adverse
effects of medicines and thereby protect patient safety, while at the
same time improving data quality and operational efficiency.

Genpact’s PVAI capabilities [1] incorporate natural language processing
and machine learning techniques to reliably and accurately extract and
process adverse event data from unstructured and partially-structured
source documents. The integration of CVW with Genpact’s PVAI offering
for automated and intelligent case processing is expected to create a
pharmacovigilance system that continually learns from the wider
healthcare delivery ecosystem, accelerates and enhances signal detection
and evaluation, and better protects patient safety.

Commonwealth Informatics is led by a widely-respected services and
development team whose products and services span signal detection,
signal evaluation, risk assessment, benefit-risk assessment, and
population health informatics. CVW consists of a set of integrated
modules that are delivered via a software as a service model.
Commonwealth Informatics developed the modules in close collaboration
with leading pharmacovigilance teams within pharmaceutical companies and
regulatory agencies. The modules provide support for generating and
assessing evidence from individual case safety reports, clinical trial
data sets, and electronic health records. CVW is used by life sciences
and biotech companies, healthcare providers, and government agencies
such as the U.S. Food and Drug Administration (FDA) and the UK Medicines
and Healthcare Products Regulatory Agency (MHRA).

“With the integration of Commonwealth Informatics’ ground-breaking
signal management solution into the Genpact PVAI suite of capabilities,
we can better help life sciences companies achieve end-to-end
transformations of their pharmacovigilance operating models, serving as
their single go-to partner,” SAID BALKRISHAN “BK” KALRA, BUSINESS
LEADER FOR LIFE SCIENCES AND HEALTHCARE AT GENPACT. “We believe that our
enhanced PVAI suite has the potential to be revolutionary in its impact
across the industry, shifting resources from transaction processing to
analyzing the effects of medicines on public health. Genpact’s PVAI
offering is currently being implemented by a number of large
pharmaceutical companies, including a top-five global pharmaceutical
leader. With the added capabilities from CI, we are excited to provide a
comprehensive solution capable of transforming pharmacovigilance.”

“Commonwealth Informatics is thrilled to join forces with Genpact and
combine our software and expertise in close collaboration with our
customers to create the future of pharmacovigilance systems,” SAID
GEOFFREY GORDON, FOUNDER AND PRESIDENT, COMMONWEALTH INFORMATICS. “We
are also excited to use this strong foundation as the basis for future
work with healthcare organizations to close the loop and realize the
full potential of a learning healthcare system.”

Genpact currently serves the majority of the top global life sciences
companies, helping pharmaceutical and medical devices companies pursue
global growth, achieve cost reduction, increase speed to market, and
improve regulatory compliance by providing a range of digital solutions,
analytics services, and business process transformation expertise.
Interested parties may learn more about Genpact’s services for life
sciences companies here [2].

Corporate Comm India(CCI Newswire)

LEAVE A REPLY

Please enter your comment!
Please enter your name here